Chipscreen Bioscience’s Epidaza (chidamide) Receives NMPA Approval for Breast Cancer Indication

 Chipscreen Bioscience’s Epidaza (chidamide) Receives NMPA Approval for Breast Cancer Indication

Chipscreen Bioscience’s Epidaza (chidamide) Receives NMPA Approval for Breast Cancer Indication

Shots:

  • The approval follows P-III ACE study assessing chidamide + exemestane demonstrated PFS benefit and the includes Chidamide + aromatase inhibitor in postmenopausal patients with HR+, HER2- advanced breast cancer (ABC) treated with endocrine therapies for recurrence or progression
  • Chidamide (CS055/HBI-8000/tucidinostat) is an orally available low-nanomolar inhibitor of cancer-associated histone deacetylase (HDAC) enzymes targeting subtype 1, 2, 3 of Class I and subtype 10 of Class IIb HDAC and has also received CFDA approval for recurrent and refractory peripheral T-cell lymphoma in Dec 2014  
  • Epidaza is currently being evaluated as monothx or in combination with chemotherapeutic/targeted agents for the treatment of various hematological tumors, solid cancers, and HIV in the United States, Japan, Korea, China, and Taiwan

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post